Clinical Trial Update: Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy [NA]

View source ↗

Summary

A clinical trial evaluating oregovomab with or without cyclophosphamide in Stage III/IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Epithelial Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Oregovomab (oregovomab)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | NA | Status: WITHDRAWN